Human peripheral blood mononuclear cell PBMC

Recently, it has been found that NO donors inhibit HIV-1 replication in acutely infected human peripheral blood mononuclear cells (PBMCs), and have an additive inhibitory effect on HIV-1 replication in combination with 3 -azido-3 -deoxythymisylate (AZT) [139, 140]. S-nitrosothiols (RSNOs) inhibit HIV-1 replication at a step in the viral replicative cycle after reverse transcription, but before or during viral protein expression through a cGMP-independent mechanism. In the latently infected U1 cell line, NO donors and intracellular NO production stimulate HIV-1 reactivation. These studies suggest that NO both inhibits HIV-1 replication in acutely infected cells and stimulates HIV-1 reactivation in chronically infected cells. Thus, NO donors may be useful in the treatment of HIV-1 disease by inhibiting acute infection, or reactivating a latent virus. 

Several benzothiadiazepines, as potent and selective TACE inhibitors, have been synthesized with variation in P1 and PI and evaluated versus porcine TACE, and the initial selectivity was assessed with counterscreens of MMP-1, MMP-2, and MMP-9. Several potent and selective inhibitors were discovered, 440 being the most active against porcine TACE. Most compounds were assessed in the human peripheral blood mononuclear cell (PBMC) assay and the human whole blood assay (WBA) to determine their ability to suppress tumor necrosis factor alpha (TNF-a). Compound 441 was found to be the most potent in the PBMC assay (IC50 = 0.35 pM), while 442 was the most active in the WBA (IC50 = 1.4 pM) <2003JME1811>. 

D Avolio A et al (2012) HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J Pharm Biomed Anal 59 109-116... 

An alternative to the traditional in vivo TDAR assay is the recently developed in vitro human lymphocyte activation (HuLA) assay using human peripheral blood mononuclear cells (PBMCs), which measures secondary influenza-specific responses. This assay is sensitive to, and can differentiate the responses of, a number of known immunosuppressive compounds with different mechanisms of action at concentrations within their respective therapeutic ranges. Various endpoints can be evaluated, including proliferation and flu antigen-specific antibody (IgM and lgG)-secreting cells (Collinge et al., 2010). 

Several are the medical applications of new EPSs, ranging from antitumor to antiviral agents polymers with immunostimulant properties have been described. Qeobacillus themodenitnficans isolated ffomVulcano island (Italy) produced an EPS with immunomodulatory and antiviral effects on human peripheral blood mononuclear cells (PBMC). The same authors have reported the studies conducted on a new EPS produced by Badllus licheniformis that showed the antiviral and the immunoregulatory effect... 

Aucubin (15) isolated from Plantago major showed immunomodulatory activity at a concentration less than 5 pM by stimulating human peripheral blood mononuclear cells (PBMC) and enhancing the secretion of interferon gamma (IFN-y) in ELISA test [176]. 

The immunomodulatory effect of a polysaccharide (HCP-2) isolated from Houttuynia cordata is described in [76]. Previous papers described the bioactivities of water extract of H. cordata [72-74], but few pharmacological studies on isolated polysaccharides have been described [75]. HCP-2 increased the secretions of interleukin-1(3 (IL-1(3), tumor necrosis factor-a (TNF-a), macrophage inhibitory proteins (MIP-la and MIP-1(3), and RANTES (regulated on activation, normal T cell expressed and secreted) in human peripheral blood mononuclear cells (PBMCs) [76]. 

Jemal, M. Rao, S. Gatz, M. Whigan, D. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC) practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis, J.Chromatogr.B, 2003, 795, 273 - 289. 

---